ranolazine has been researched along with Angor Pectoris in 188 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.53) | 18.7374 |
| 1990's | 13 (6.91) | 18.2507 |
| 2000's | 92 (48.94) | 29.6817 |
| 2010's | 76 (40.43) | 24.3611 |
| 2020's | 6 (3.19) | 2.80 |
| Authors | Studies |
|---|---|
| Cesar, LAM; Dourado, LOC; Gowdak, LHW; Grobe, SF; Moreno, CPD | 1 |
| Argirò, A; Baldini, K; Cappelli, F; Coppini, R; Dei, LL; Favilli, S; Ferrantini, C; Gabriele, M; Marchi, A; Marchionni, N; Maurizi, N; Olivotto, I; Passantino, S; Tassetti, L; Tomberli, A; Zampieri, M; Zocchi, C | 1 |
| Chen, T; Fang, X; Huang, J; Xu, X; Zhao, Q; Zheng, J; Zhu, H | 1 |
| Cruz Rodriguez, JB; Kar, S | 1 |
| Khandelwal, A; Pargaonkar, VS; Schnittger, I; Tremmel, JA | 1 |
| Arndt, TL; Bennett, NM; Garberich, RF; Henry, TD; Schmidt, CW; Storey, KM; Traverse, JH; Wang, J | 1 |
| Anderson, RD; Bairey Merz, CN; Cook-Wiens, G; Handberg, EM; Pepine, CJ; Petersen, JW; Quesada, O; Samuels, B; Shufelt, C; Suppogu, N; Wei, J | 1 |
| Alexander, KP; Anstrom, KJ; Ben-Yehuda, O; Fanaroff, AC; James, SK; Mark, DB; Ohman, EM; Prather, K; Stone, GW; Weisz, G | 1 |
| Graham, MM; Pearson, GJ; Turgeon, RD | 1 |
| Borzi, M; Grilli, G; Intorcia, A; Perrone, MA; Romeo, F; Sergi, D | 1 |
| Arnold, SV; Breeding, T; Gosch, KL; Jones, PG; Patel, KK; Peri-Okonny, PA; Spertus, JA | 1 |
| Bairey Merz, CN; Berman, DS; Cook-Wiens, G; Elgendy, IY; Handberg, EM; Minissian, MB; Nelson, MD; Pepine, CJ; Rambarat, CA; Shaw, LJ; Thomson, LEJ; Wei, J | 1 |
| Turgeon, RD | 1 |
| Alexander, KP; Barefoot, J; Ben-Yehuda, O; Brucker, A; Davidson-Ray, L; Fanaroff, AC; Mark, DB; Ohman, EM; Prather, K; Stone, GW; Weisz, G; Williams, RB; Wojdyla, D | 1 |
| Marciniak, TA; Serebruany, V | 1 |
| Gosch, K; Grantham, JA; Karmpaliotis, D; Kirtane, A; Lombardi, W; Moses, J; Nicholson, W; Peri-Okonny, PA; Salisbury, AC; Sapontis, J; Spertus, JA | 1 |
| Boden, WE; Rasalingam, R | 1 |
| Arnold, SV; Cohen, DJ; Grantham, JA; Hirai, T; Jones, P; Karmpaliotis, D; Lombardi, W; Moses, J; Nicholson, WJ; Patterson, C; Qintar, M; Salisbury, AC; Sapontis, J; Sheehy, J; Spertus, JA; Tang, Y | 1 |
| Peters, CH; Rajamani, S; Ruben, PC; Sokolov, S | 1 |
| Crea, F; Di Franco, A; Di Monaco, A; Lamendola, P; Lanza, GA; Nerla, R; Sarullo, FM; Sestito, A; Tarzia, P; Villano, A | 1 |
| Jacobshagen, C | 1 |
| Burns, TL; Hilleman, DE; Ling, H; Packard, KA | 1 |
| Jones, DA; Timmis, A; Wragg, A | 1 |
| Cice, G; Cirillo, A; D'Amore, C; del Guercio, L; Della Ratta, GL; Fimiani, L; Formisano, T; Musella, F; Pellegrino, AM; Perrone-Filardi, P; Rosano, G; Savarese, G; Trimarco, B; Vitagliano, A | 1 |
| Hidalgo-Vega, A; Ramos-Goñi, JM; Villoro, R | 1 |
| Alexander, KP; Ben-Yehuda, O; Debruyne, B; Farzaneh-Far, R; Lerman, A; Mahmud, E; Montalescot, G; Ohman, EM; Olmsted, A; Stone, GW; Walker, GA; Weisz, G; White, HD | 1 |
| Galderisi, M; Mafrici, A | 1 |
| Bassetti, B; Capogrossi, M; Gambini, E; Gennari, M; Pompilio, G | 1 |
| Acharjee, S; Codolosa, JN; Figueredo, VM | 1 |
| Arndt, TL; Bennett, NM; Garberich, RF; Henry, TD; Iyer, V; Johnson, RK; Lips, A; Morgan, JM; Poulose, AK; Traverse, JH | 1 |
| Arnold, SV; Belardinelli, L; Jones, PG; Kosiborod, M; Li, Y; Spertus, JA; Yue, P | 1 |
| Kassardjian, CD; Milone, M; Tian, X; Vladutiu, G; Wong, LJ | 1 |
| Bacchni, S; Bongo, AS; Cavallino, C; Facchini, M; Lupi, A; Rametta, F; Rognoni, A; Rosso, R; Veia, A | 1 |
| Belardinelli, L; Farzaneh-Far, R; Gutierrez, JA; Karwatowska-Prokopczuk, E; Morrow, DA; Murphy, SA; Scirica, BM; Walker, G | 1 |
| Head, SJ; Kappetein, AP | 1 |
| Alexander, KP; Ben-Yehuda, O; Dressler, O; Farzaneh-Far, R; Généreux, P; Iñiguez, A; James, S; Ohman, EM; Osmukhina, A; Shechter, M; Stone, GW; Weisz, G; Zurakowski, A | 1 |
| Alexander, KP; Anstrom, KJ; Ben-Yehuda, O; Davidson-Ray, L; Farzaneh-Far, R; James, S; Mark, DB; Mulkay, AJ; Ohman, EM; Osmukhina, A; Prather, K; Stone, GW; Weisz, G; Witkowski, A | 1 |
| Anderson, RD; Bairey Merz, CN; Berman, DS; Brown, GH; Cook-Wiens, G; Handberg, EM; Mehta, PK; Minissian, MB; Pepine, CJ; Petersen, JW; Rogatko, A; Shaw, LJ; Shufelt, CL; Shuster, JJ; Thomson, LE; Wei, J | 1 |
| Gourzoulidis, G; Kanakakis, J; Kourlaba, G; Maniadakis, N; Parissis, J; Vlachopoulos, C | 1 |
| Généreux, P; Redfors, B | 1 |
| Grätzel, P | 1 |
| Chatzizisis, YS; Giannoglou, GD; Giannopoulos, AA | 1 |
| Colombo, A; Fragasso, G; Fumero, A; Giannini, F; Godino, C; Maranta, F; Margonato, A; Oppizzi, M; Slavich, M | 1 |
| Allard, M; Ben-Yehuda, O; Berg, J; Gottwald, M; Jochelson, P; Juan, A; Pannacciulli, N; Shao, Y; Zack, J; Zhang, H | 1 |
| Gentry, JL; Hurdle, M; Mentz, RJ; Wang, A | 1 |
| Banerjee, A; Banerjee, K; Ghosh, RK; Gupta, A; Kamatam, S | 1 |
| Davis, MK; Ignaszewski, A; Toma, M; Yeung, DF | 1 |
| Conti, CR | 5 |
| Boden, WE; Eid, F | 1 |
| Arora, R; Jawad, E | 1 |
| Gu, J; Jiang, Y; Li, H; Li, P; Piao, R; Zhao, L | 1 |
| Stone, PH | 1 |
| Nash, DT; Nash, SD | 1 |
| Keating, GM | 1 |
| Arora, RR; Patel, PD | 1 |
| César, LA; Gowdak, LH; Mansur, AP | 1 |
| Barone, L; Crea, F; Di Monaco, A; Lamendola, P; Lanza, GA; Pisanello, C | 1 |
| Maier, LS | 1 |
| Badger, T; Barry, WH; Kadono, T; Matsuoka, N; Rodesch, CK; Rollins, D; Yamada, S; Zhang, XQ | 1 |
| Braunwald, E; Buros, JL; Chaitman, BR; Karwatowska-Prokopczuk, E; Morrow, DA; Murphy, SA; Scirica, BM; Wilson, SR | 1 |
| Chen, BS; Hsu, TI; Lo, YC; Peng, H; Wu, SN | 1 |
| Milne, HC; Vallerand, AH | 1 |
| Arcidi, JM; Belardinelli, L; Dhalla, AK; Hale, SL; Hwang, H; Kloner, RA; Shryock, JC; Simkhovich, BZ | 1 |
| Belardinelli, L; Bhandari, A; Dhalla, AK; Dow, J; Kloner, RA; Shryock, JC; Wang, WQ | 1 |
| Belardinelli, L; Blackburn, B; Heo, J; Iskandrian, AE; Venkataraman, R | 1 |
| Klocke, FJ | 1 |
| Ahlehoff, O; Hansen, PR | 1 |
| Arnold, SV; Braunwald, E; Chan, PS; Cohen, DJ; Lei, Y; Mahoney, EM; Morrow, DA | 1 |
| Kloner, RA; Reffelmann, T | 1 |
| Aslam, S; Gray, D | 1 |
| Dib-Hajj, SD; Estacion, M; Waxman, SG | 1 |
| Bhandari, A; Dow, JS; Kloner, RA | 1 |
| Battler, A; Dvir, D | 1 |
| D'Amico, AV; Goldhaber, SZ | 1 |
| Figueredo, VM; Holderbach, P; Morris, DL; Murdock, E; Pressman, GS; Romero-Corral, A | 1 |
| Hoppe, UC; Kochanek, M; Michels, G | 1 |
| Ezekiel, TO; Hylton, AC | 1 |
| Reddy, BM; Schwartzbard, AZ; Weintraub, HS | 1 |
| Bălan, H | 1 |
| Baczkó, I; Bussek, A; Husti, Z; Jost, N; Koncz, I; Papp, JG; Ravens, U; Szél, T; Varró, A; Virág, L; Wettwer, E | 1 |
| Köster, R; Meinertz, T | 1 |
| Carbajal, EV; Deedwania, PC | 1 |
| Caballero, R; Delpón, E; Tamargo, J | 1 |
| Bonadei, I; Cas, LD; D'Aloia, A; Piovanelli, B; Quinzani, F; Rovetta, R; Vizzardi, E | 1 |
| Athauda-Arachchi, P; Lang, C | 1 |
| Ahn, HS; Choi, BH; Choi, JS; Hahn, SJ; Kim, HJ | 1 |
| Belardinelli, L; Nieminen, T; Pegler, JR; Tavares, CA; Verrier, RL | 1 |
| Boden, WE; Friedewald, VE; Roberts, WC; Stone, GW; Yancy, CW | 1 |
| Kaliebe, J; Larrain, G; Murdock, DK | 1 |
| Defelice, A; Girton, J; Glasser, SP; Hung, J; Lawrence, J; Lipicky, RJ; Mangano, D; Obot, E; Targum, S; Throckmorton, D; Willard, J | 1 |
| Custodis, F; Laufs, U | 1 |
| Bonadei, I; Bontempi, L; Curnis, A; D'Aloia, A; Dei Cas, L; Quinzani, F; Rovetta, R; Vizzardi, E | 1 |
| Buysman, EK; Gomez Rey, G; Phelps, CE | 1 |
| Athanasiadis, A; Sechtem, U | 1 |
| Gaudio, C; Greco, C; Marazzi, G; Pasceri, V; Pelliccia, F; Rosano, G | 1 |
| De Rosa, G; Groppa, F; Iafrate, M; Marzot, F; Padrini, R; Panfili, M; Secco, S | 1 |
| Bauersachs, J | 1 |
| Blankstein, R; Bui, AH; M Blum, R; Southard, RA | 1 |
| Hawwa, N; Menon, V | 1 |
| Li, HD; Peng, WX; Tan, QY; Zhang, J; Zhang, QZ; Zhu, RH | 1 |
| Maisch, B; Rupp, H; Zarain-Herzberg, A | 1 |
| Chaitman, BR | 3 |
| McCarty, MF | 1 |
| Armstrong, PW; Borer, JS; Fleming, T; Nissen, SE | 1 |
| Chaitman, BR; Chumakova, G; Kuch, J; Parker, JO; Pepine, CJ; Skettino, SL; Skopal, J; Wang, W; Wolff, AA | 1 |
| Berger, P | 1 |
| Kolata, G | 1 |
| Frenneaux, M; Horowitz, J; Lee, L | 1 |
| Chaitman, BR; Hanley, P; Hebert, DA; Kuch, J; Meluzin, J; Nelson, JJ; Parker, JO; Pepine, CJ; Skettino, SL; Wang, W; Wolff, AA | 1 |
| Busti, AJ; Hooper, JS | 1 |
| Pechlaner, C; Wiedermann, C | 1 |
| Sweeney, M | 1 |
| Antzelevitch, C; Belardinelli, L; Burashnikov, A; Cordeiro, JM; Di Diego, JM; Fish, JM; Fraser, H; Goodrow, RJ; Perez, G; Scornik, F; Wu, L; Zygmunt, AC | 1 |
| Gratsianskiĭ, NA | 1 |
| Salazar, R; Taegtmeyer, H | 1 |
| Cocco, G; Pouleur, H; Rousseau, MF; Wolff, AA | 1 |
| Marzilli, M | 1 |
| Chaitman, BR; Crager, M; Timmis, AD | 1 |
| Stanley, WC | 2 |
| McCullough, PA | 2 |
| Aguiar-Souto, P; Ortigosa-Aso, FJ; Silva-Melchor, L | 1 |
| Cooper-DeHoff, R; Pepine, CJ | 1 |
| Barsness, GW; Yang, EH | 1 |
| Inglis, S; Stewart, S | 1 |
| Gaffney, SM | 1 |
| Makielski, JC; Valdivia, CR | 1 |
| Fisher, E; Tafreshi, MJ | 1 |
| Keam, SJ; Siddiqui, MA | 2 |
| Jerling, M | 1 |
| Belardinelli, L; Hintze, TH; Messina, E; Ochoa, M; Serpillon, S; Shryock, J; Xu, X; Zhao, G | 1 |
| Marx, C; Sweeney, M | 1 |
| Abrams, J; Jones, CA; Kirkpatrick, P | 1 |
| Blokhin, A; Gratsiansky, NA; Huang, IZ; Meng, L; Stone, PH | 1 |
| Cairns, JA | 1 |
| McBride, BF; Zerumsky, K | 1 |
| Chaitman, B; Vetrovec, GW; Wenger, NK | 1 |
| Gilbert, M; Laustsen, G; Wimett, L | 1 |
| Cheng, JW | 1 |
| Crager, MR; Koren, MJ; Sweeney, M | 1 |
| Braunwald, E; Budaj, A; Karwatowska-Prokopczuk, E; McCabe, CH; Morrow, DA; Murphy, SA; Scirica, BM; Skene, A; Varshavsky, S; Wolff, AA | 1 |
| Newby, LK; Peterson, ED | 1 |
| Jackson, G | 1 |
| Morrow, DA; Scirica, BM | 1 |
| Scirica, BM | 1 |
| Belardinelli, L; Braunwald, E; Gersh, BJ; Hedgepeth, CM; Hod, H; McCabe, CH; Molhoek, P; Morrow, DA; Murphy, SA; Scirica, BM; Verheugt, FW | 1 |
| Dobesh, PP; Trujillo, TC | 1 |
| Melloni, C; Newby, LK | 1 |
| Bhandari, B; Subramanian, L | 1 |
| Bobba, VR; Carbajal, EV; Deedwania, PC | 1 |
| Chaitman, BR; Sano, J | 1 |
| Belardinelli, L; Hale, SL; Kloner, RA; Shryock, JC; Sweeney, M | 1 |
| Bueno, O; Zavecz, JH | 1 |
| Ribeiro, C | 1 |
| Hayashida, W; Pouleur, H; Rousseau, MF; van Eyll, C | 1 |
| Chierchia, SL; Fragasso, G | 1 |
| Black, SC; Chou, AY; Gralinski, MR; Kilgore, KS; Lucchesi, BR; McCormack, JG | 1 |
| Chiang, YK; Ezekowitz, M; Fenney, L; Thadani, U | 1 |
| Clarke, B; McCormack, JG; Patmore, L; Spedding, M | 1 |
| Bagger, JP; Bøtker, HE; Nielsen, TT; Thomassen, A | 1 |
| McCormack, JG; Stanley, WC; Wolff, AA | 1 |
| Akahane, M; Endo, T; Komatsu, H; Maruyama, K; Murakami, M; Wang, JX | 1 |
| Pepine, CJ; Wolff, AA | 1 |
| Hill, JA; Schofield, RS | 1 |
| Clark, AL; Cleland, JG; Coletta, AP; Louis, AA; Manousos, IR | 1 |
| Bouvy, T; Cheron, P; Cocco, G; Detry, JM; Pouleur, H; Rousseau, MF; Williams, G | 1 |
| Dasgupta, P; Hughes, LO; Jain, D; Lahiri, A; Raftery, EB | 1 |
| Allely, MC; Alps, BJ | 1 |
66 review(s) available for ranolazine and Angor Pectoris
| Article | Year |
|---|---|
Effects of the Antianginal Drugs Ranolazine, Nicorandil, and Ivabradine on Coronary Microvascular Function in Patients With Nonobstructive Coronary Artery Disease: A Meta-analysis of Randomized Controlled Trials.
Topics: Angina Pectoris; Cardiovascular Agents; Coronary Artery Disease; Humans; Ivabradine; Myocardial Ischemia; Nicorandil; Randomized Controlled Trials as Topic; Ranolazine; Treatment Outcome | 2019 |
Management of Angina Post Percutaneous Coronary Intervention.
Topics: Angina Pectoris; Calcium Channel Blockers; Coronary Artery Disease; Echocardiography, Stress; Humans; Magnetic Resonance Imaging; Percutaneous Coronary Intervention; Ranolazine | 2020 |
Pharmacologic Treatment of Patients With Myocardial Ischemia With No Obstructive Coronary Artery Disease.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Cardiovascular Agents; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Ischemia; Nicorandil; Nitrates; Quality of Life; Ranolazine; Vasodilator Agents | 2018 |
[Late sodium current and calcium overload--pathogenesis and adequate treatment].
Topics: Acetanilides; Adrenergic beta-Antagonists; Angina Pectoris; Atrial Fibrillation; Benzazepines; Calcium; Calcium Channel Blockers; Cardiovascular Agents; Coronary Artery Disease; Electrocardiography; Endothelium, Vascular; Heart Failure, Diastolic; Humans; Hypercalcemia; Ivabradine; Myocardial Ischemia; Nitrates; Piperazines; Ranolazine; Sodium; Sodium Channels; Sodium-Calcium Exchanger | 2013 |
Novel drugs for treating angina.
Topics: Acetanilides; Angina Pectoris; Benzazepines; Enzyme Inhibitors; Heart Rate; Humans; Ivabradine; Nicorandil; Piperazines; Ranolazine; Trimetazidine; Vasodilator Agents | 2013 |
Effects of ranolazine in symptomatic patients with stable coronary artery disease. A systematic review and meta-analysis.
Topics: Acetanilides; Angina Pectoris; Blood Pressure; Coronary Artery Disease; Heart Rate; Humans; Piperazines; Randomized Controlled Trials as Topic; Ranolazine | 2013 |
Emerging treatment options for refractory angina pectoris: ranolazine, shock wave treatment, and cell-based therapies.
Topics: Acetanilides; Angina Pectoris; Animals; Endothelial Cells; High-Energy Shock Waves; Humans; Neovascularization, Physiologic; Piperazines; Ranolazine; Regeneration; Sodium Channel Blockers; Stem Cell Transplantation; Treatment Outcome | 2014 |
Update on ranolazine in the management of angina.
Topics: Acetanilides; Angina Pectoris; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Chronic Disease; Cost Savings; Cost-Benefit Analysis; Drug Costs; Hospital Costs; Hospitalization; Humans; Piperazines; Ranolazine; Sodium Channel Blockers; Treatment Outcome | 2014 |
New Anti-Anginal Drugs: Ranolazine.
Topics: Angina Pectoris; Animals; Cardiovascular Agents; Controlled Clinical Trials as Topic; Diastole; Humans; Ranolazine; Sodium Channel Blockers | 2015 |
Pharmacological approaches of refractory angina.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Calcium Channel Blockers; Cardiovascular Agents; Coronary Artery Disease; Fibrinolytic Agents; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Nicorandil; Nitrates; Ranolazine | 2016 |
Role of Ranolazine in cardiovascular disease and diabetes: Exploring beyond angina.
Topics: Aged; Angina Pectoris; Atrial Fibrillation; Cardiovascular Diseases; Chronic Disease; Diabetes Mellitus; Female; Humans; Male; Middle Aged; Prognosis; Randomized Controlled Trials as Topic; Ranolazine; Risk Assessment; Role; Sodium Channel Blockers; Survival Analysis; Treatment Outcome | 2017 |
Chronic stable angina pectoris.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Acetanilides; Angina Pectoris; Antihypertensive Agents; Benzazepines; Bosentan; Chronic Disease; Counterpulsation; Cyclic Nucleotide-Gated Cation Channels; Exercise Test; Heart Murmurs; Humans; Ivabradine; Myocardial Contraction; Myocardial Ischemia; Myocardial Revascularization; Myocardium; Nicorandil; Oxygen Consumption; Perhexiline; Piperazines; Protein Kinase Inhibitors; Ranolazine; Sulfonamides; Trimetazidine; Vasodilator Agents | 2008 |
Ranolazine: new paradigm for management of myocardial ischemia, myocardial dysfunction, and arrhythmias.
Topics: Acetanilides; Angina Pectoris; Animals; Arrhythmias, Cardiac; Cardiomyopathies; Drug Therapy, Combination; Heart Failure; Humans; Myocardial Ischemia; Piperazines; Ranolazine | 2008 |
Ranolazine for chronic stable angina.
Topics: Acetanilides; Aged; Aged, 80 and over; Angina Pectoris; Chronic Disease; Dosage Forms; Drug-Related Side Effects and Adverse Reactions; Enzyme Inhibitors; Female; Humans; Male; Middle Aged; Piperazines; Ranolazine; Sex Factors | 2008 |
Ranolazine: a review of its use in chronic stable angina pectoris.
Topics: Acetanilides; Angina Pectoris; Cardiovascular Agents; Chronic Disease; Delayed-Action Preparations; Humans; Piperazines; Ranolazine | 2008 |
Utility of ranolazine in chronic stable angina patients.
Topics: Acetanilides; Angina Pectoris; Cardiovascular Agents; Chronic Disease; Diabetes Complications; Glycated Hemoglobin; Humans; Piperazines; Ranolazine; Treatment Outcome | 2008 |
The metabolic treatment of patients with coronary artery disease: effects on quality of life and effort angina.
Topics: Acetanilides; Angina Pectoris; Animals; Carnitine; Clinical Trials as Topic; Coronary Artery Disease; Dichloroacetic Acid; Humans; Piperazines; Quality of Life; Ranolazine; Ribose; Surveys and Questionnaires; Trimetazidine; Vasodilator Agents | 2009 |
[Mechanisms of myocardial cell protection from ischemia/reperfusion injury and potential clinical implications].
Topics: Acetanilides; Acute Coronary Syndrome; Angina Pectoris; Animals; Apoptosis; Cell Death; Collateral Circulation; Disease Models, Animal; Humans; Ischemic Preconditioning, Myocardial; Meta-Analysis as Topic; Myocardial Infarction; Myocardial Ischemia; Myocardial Reperfusion Injury; Myocardium; Myocytes, Cardiac; Oxygen Consumption; Piperazines; Randomized Controlled Trials as Topic; Ranolazine; Trimetazidine; Vasodilator Agents | 2009 |
A novel mechanism for the treatment of angina, arrhythmias, and diastolic dysfunction: inhibition of late I(Na) using ranolazine.
Topics: Acetanilides; Angina Pectoris; Animals; Arrhythmias, Cardiac; Clinical Trials as Topic; Heart Failure, Diastolic; Humans; Piperazines; Ranolazine; Sodium; Sodium Channel Blockers; Sodium Channels; Sodium-Calcium Exchanger | 2009 |
Chronic angina and the treatment with ranolazine: facts and recommendations.
Topics: Acetanilides; Angina Pectoris; Chronic Disease; Enzyme Inhibitors; Humans; Piperazines; Ranolazine | 2009 |
Ranolazine: an anti-anginal drug with further therapeutic potential.
Topics: Acetanilides; Angina Pectoris; Chronic Disease; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Approval; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Nitroglycerin; Piperazines; Randomized Controlled Trials as Topic; Ranolazine; Survival Rate; Treatment Outcome; United States | 2010 |
Ranolazine (Ranexa) in the treatment of chronic stable angina.
Topics: Acetanilides; Angina Pectoris; Cardiovascular Agents; Chronic Disease; Coronary Artery Bypass; Drug Therapy, Combination; Humans; Piperazines; Randomized Controlled Trials as Topic; Ranolazine | 2010 |
Conventional and novel drug therapeutics to relief myocardial ischemia.
Topics: Acetanilides; Adrenergic beta-Antagonists; Angina Pectoris; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzazepines; Calcium Channel Blockers; Cardiovascular Agents; Cardiovascular System; Coronary Artery Disease; Hemodynamics; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ivabradine; Nicorandil; Nitrates; Piperazines; Ranolazine | 2010 |
[Ranolazine--an additional anti-anginal drug].
Topics: Acetanilides; Angina Pectoris; Atrial Fibrillation; Biological Availability; Blood Pressure; Double-Blind Method; Enzyme Inhibitors; Heart Failure, Diastolic; Heart Rate; Humans; Metabolic Clearance Rate; Piperazines; Randomized Controlled Trials as Topic; Ranolazine | 2010 |
Ranolazine: a new approach to treating an old problem.
Topics: Acetanilides; Angina Pectoris; Angina, Unstable; Anti-Arrhythmia Agents; Atrial Fibrillation; Chronic Disease; Evidence-Based Medicine; Heart Diseases; Heart Failure, Diastolic; Humans; Myocardial Infarction; Piperazines; Practice Guidelines as Topic; Ranolazine; Sodium Channel Blockers; Treatment Outcome | 2010 |
At the dawn of a new era in treating angina pectoris, or just another antianginal drug? Some considerations about ranolazine.
Topics: Acetanilides; Angina Pectoris; Enzyme Inhibitors; Humans; Piperazines; Ranolazine; Secondary Prevention | 2010 |
[New agents for the therapy of angina pectoris].
Topics: Acetanilides; Angina Pectoris; Benzazepines; Coronary Artery Disease; Cyclic Nucleotide-Gated Cation Channels; Double-Blind Method; Drug Approval; Enzyme Inhibitors; Humans; Ivabradine; Nicorandil; Piperazines; Randomized Controlled Trials as Topic; Ranolazine; Vasodilator Agents | 2011 |
Medical therapy versus myocardial revascularization in chronic coronary syndrome and stable angina.
Topics: Acetanilides; Adrenergic beta-Antagonists; Angina Pectoris; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Calcium Channel Blockers; Cardiovascular Agents; Coronary Disease; Drug Therapy, Combination; Humans; Hypolipidemic Agents; Ivabradine; Myocardial Revascularization; Nitrates; Piperazines; Ranolazine; Treatment Outcome | 2011 |
Ranolazine: an antianginal drug with antiarrhythmic properties.
Topics: Acetanilides; Angina Pectoris; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Humans; Piperazines; Ranolazine; Sodium Channel Blockers | 2011 |
Is randomization to placebo safe? Risk in placebo-controlled angina trials: angina risk meta-analysis.
Topics: Acetanilides; Adrenergic beta-Antagonists; Angina Pectoris; Angina, Unstable; Calcium Channel Blockers; Cardiovascular Diseases; Drug Approval; Enzyme Inhibitors; Female; Hospitalization; Humans; Male; Medical Records; Middle Aged; Nitrates; Observer Variation; Patient Dropouts; Patient Safety; Piperazines; Placebos; Randomized Controlled Trials as Topic; Ranolazine; Risk Assessment; Risk Factors; Treatment Failure | 2011 |
[Conservative therapy of patients with stable coronary heart disease].
Topics: Acetanilides; Adrenergic beta-Antagonists; Angina Pectoris; Calcium Channel Blockers; Combined Modality Therapy; Coronary Disease; Drug Incompatibility; Enzyme Inhibitors; Heart Failure; Heart Rate; Humans; Life Style; Myocardial Infarction; Myocardial Revascularization; Nitrates; Piperazines; Ranolazine; Treatment Outcome | 2012 |
A focus on antiarrhythmic properties of ranolazine.
Topics: Acetanilides; Action Potentials; Angina Pectoris; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Heart Atria; Heart Ventricles; Humans; Ion Channels; Membrane Transport Modulators; Piperazines; Ranolazine | 2012 |
Ranolazine: clinical applications and therapeutic basis.
Topics: Acetanilides; Action Potentials; Angina Pectoris; Animals; Cardiovascular Diseases; Humans; Piperazines; Randomized Controlled Trials as Topic; Ranolazine; Sodium Channel Blockers | 2013 |
The use of partial fatty acid oxidation inhibitors for metabolic therapy of angina pectoris and heart failure.
Topics: Acetanilides; Angina Pectoris; Animals; Calcium; Cardiovascular Agents; Clinical Trials as Topic; Enzyme Inhibitors; Epoxy Compounds; Fatty Acids; Gene Expression; Glucose; Heart Failure; Humans; Hypoglycemic Agents; Methylhydrazines; Myocytes, Cardiac; Oxidation-Reduction; Piperazines; Ranolazine; Rats; Rats, Wistar; Sarcoplasmic Reticulum; Trimetazidine; Up-Regulation; Vasodilator Agents | 2002 |
Measuring antianginal drug efficacy using exercise testing for chronic angina: improved exercise performance with ranolazine, a pFOX inhibitor.
Topics: Acetanilides; Adrenergic beta-Antagonists; Angina Pectoris; Chronic Disease; Enzyme Inhibitors; Exercise; Exercise Test; Hemodynamics; Humans; Piperazines; Randomized Controlled Trials as Topic; Ranolazine; Risk Factors; Treatment Outcome; United States | 2002 |
Metabolic manipulation in ischaemic heart disease, a novel approach to treatment.
Topics: Acetanilides; Adrenergic beta-Antagonists; Angina Pectoris; Cardiovascular Agents; Drug Therapy, Combination; Enzyme Inhibitors; Epoxy Compounds; Glucose; Humans; Hypoglycemic Agents; Insulin; Myocardial Ischemia; Myocardium; Perhexiline; Piperazines; Potassium; Ranolazine; Trimetazidine | 2004 |
Electrophysiologic properties and antiarrhythmic actions of a novel antianginal agent.
Topics: Acetanilides; Action Potentials; Angina Pectoris; Animals; Electrophysiologic Techniques, Cardiac; Humans; Ion Channels; Long QT Syndrome; Piperazines; Ranolazine; Stereoisomerism; Torsades de Pointes | 2004 |
Ranolazine: new approach for the treatment of stable angina pectoris.
Topics: Acetanilides; Angina Pectoris; Enzyme Inhibitors; Humans; Piperazines; Ranolazine | 2005 |
Chronic angina: new medical options for treatment.
Topics: Acetanilides; Angina Pectoris; Cardiovascular Agents; Chronic Disease; Enzyme Inhibitors; Humans; Piperazines; Ranolazine; Trimetazidine; Vasodilator Agents | 2005 |
Evolving treatment strategies for chronic refractory angina.
Topics: Acetanilides; Angina Pectoris; Arginine; Benzazepines; Cardiovascular Agents; Chronic Disease; Combined Modality Therapy; Counterpulsation; Electric Stimulation Therapy; Humans; Ivabradine; Myocardial Revascularization; Piperazines; Randomized Controlled Trials as Topic; Ranolazine; Spinal Cord | 2006 |
Metabolic therapeutics in angina pectoris: history revisited with perhexiline.
Topics: Acetanilides; Angina Pectoris; Calcium Channel Blockers; Cardiovascular Agents; Carnitine O-Palmitoyltransferase; Drug Monitoring; Epoxy Compounds; Fatty Acids; Half-Life; Humans; Metabolic Clearance Rate; Nurse's Role; Nursing Assessment; Patient Education as Topic; Patient Selection; Perhexiline; Piperazines; Randomized Controlled Trials as Topic; Ranolazine; Treatment Outcome; Trimetazidine; Vasodilator Agents | 2006 |
Ranolazine, a novel agent for chronic stable angina.
Topics: Acetanilides; Angina Pectoris; Chronic Disease; Clinical Trials as Topic; Enzyme Inhibitors; Guidelines as Topic; Humans; Piperazines; Ranolazine | 2006 |
Ranolazine: a new approach to management of patients with angina.
Topics: Acetanilides; Angina Pectoris; Clinical Trials as Topic; Energy Metabolism; Humans; MEDLINE; Myocardium; Piperazines; Ranolazine; Treatment Outcome | 2006 |
Ranolazine: a review of its use in chronic stable angina pectoris.
Topics: Acetanilides; Angina Pectoris; Cardiovascular Agents; Chronic Disease; Humans; Piperazines; Randomized Controlled Trials as Topic; Ranolazine | 2006 |
Ranolazine: focusing on angina pectoris.
Topics: Acetanilides; Angina Pectoris; Enzyme Inhibitors; Humans; Piperazines; Randomized Controlled Trials as Topic; Ranolazine | 2006 |
Clinical pharmacokinetics of ranolazine.
Topics: Acetanilides; Angina Pectoris; Clinical Trials as Topic; Enzyme Inhibitors; Humans; Piperazines; Ranolazine | 2006 |
Inhibition of sodium-dependent calcium overload to treat myocardial ischemia.
Topics: Acetanilides; Angina Pectoris; Enzyme Inhibitors; Homeostasis; Humans; Myocardial Ischemia; Piperazines; Ranolazine; Sodium Channel Blockers; Sodium-Calcium Exchanger | 2006 |
Ranolazine for the treatment of chronic angina and potential use in other cardiovascular conditions.
Topics: Acetanilides; Administration, Oral; Angina Pectoris; Biological Availability; Cardiovascular Diseases; Chronic Disease; Delayed-Action Preparations; Enzyme Inhibitors; Humans; Piperazines; Ranolazine | 2006 |
Ranolazine: augmenting the antianginal armamentarium.
Topics: Acetanilides; Angina Pectoris; Humans; Piperazines; Ranolazine | 2006 |
Treatment options for refractory angina in patients who are not candidates for revascularization.
Topics: Acetanilides; Angina Pectoris; Combined Modality Therapy; Counterpulsation; Electric Stimulation Therapy; Enzyme Inhibitors; Humans; Myocardial Revascularization; Piperazines; Ranolazine; Spinal Cord | 2006 |
Spotlight on ranolazine in chronic stable angina pectoris.
Topics: Acetanilides; Administration, Oral; Angina Pectoris; Chronic Disease; Delayed-Action Preparations; Humans; Piperazines; Randomized Controlled Trials as Topic; Ranolazine; Treatment Outcome; Vasodilator Agents | 2006 |
Ranolazine in the management of chronic stable angina.
Topics: Acetanilides; Angina Pectoris; Clinical Trials as Topic; Enzyme Inhibitors; Humans; Piperazines; Ranolazine; Sodium Channel Blockers | 2006 |
Ranolazine for the management of coronary artery disease.
Topics: Acetanilides; Angina Pectoris; Clinical Trials as Topic; Enzyme Inhibitors; Humans; Piperazines; Ranolazine; Treatment Outcome | 2006 |
Ranolazine in patients with angina and coronary artery disease.
Topics: Acetanilides; Angina Pectoris; Coronary Artery Disease; Enzyme Inhibitors; Humans; Piperazines; Randomized Controlled Trials as Topic; Ranolazine; Risk Factors; Treatment Outcome | 2007 |
Ranolazine in patients with coronary artery disease.
Topics: Acetanilides; Angina Pectoris; Coronary Artery Disease; Humans; Piperazines; Ranolazine | 2007 |
Ranolazine: a new option in the management of chronic stable angina.
Topics: Acetanilides; Angina Pectoris; Chronic Disease; Delayed-Action Preparations; Drug Interactions; Enzyme Inhibitors; Humans; Piperazines; Randomized Controlled Trials as Topic; Ranolazine | 2007 |
Ranolazine, a partial fatty acid oxidation inhibitor, its potential benefit in angina and other cardiovascular disorders.
Topics: Acetanilides; Angina Pectoris; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Fatty Acids; Heart Failure; Humans; Oxidation-Reduction; Piperazines; Ranolazine | 2007 |
Trials and tribulations associated with angina and traditional therapeutic approaches.
Topics: Acetanilides; Adrenergic beta-Antagonists; Angina Pectoris; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Coronary Artery Bypass; Drug Therapy, Combination; Enzyme Inhibitors; Exercise; Humans; Hypolipidemic Agents; Nitro Compounds; Piperazines; Ranolazine; Risk Reduction Behavior; Vasodilator Agents | 2007 |
Novel therapeutic approaches to treating chronic angina in the setting of chronic ischemic heart disease.
Topics: Acetanilides; Adrenergic beta-Antagonists; Angina Pectoris; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Calcium Channel Blockers; Chronic Disease; Enzyme Inhibitors; Humans; Ivabradine; Myocardial Ischemia; Nicorandil; Nitro Compounds; Piperazines; Ranolazine; rho-Associated Kinases; Sinoatrial Node; Trimetazidine; Vasodilator Agents | 2007 |
Late sodium current inhibition as a new cardioprotective approach.
Topics: Acetanilides; Angina Pectoris; Animals; Blood Pressure; Disease Models, Animal; Enzyme Inhibitors; Heart Rate; Humans; Myocardial Infarction; Myocytes, Cardiac; Piperazines; Ranolazine; Sodium; Sodium Channel Blockers; Sodium Channels | 2008 |
Pharmacologic therapy of angina pectoris.
Topics: Acetanilides; Adrenergic beta-Antagonists; Angina Pectoris; Aspirin; Calcium Channel Blockers; Drug Therapy, Combination; Enoximone; Heparin; Humans; Isosorbide Dinitrate; Niacinamide; Nicorandil; Nitroglycerin; Piperazines; Ranolazine; Vasodilator Agents | 1995 |
Metabolic management of ischaemic heart disease.
Topics: Acetanilides; Adrenergic beta-Antagonists; Angina Pectoris; Calcium Channel Blockers; Carnitine; Energy Metabolism; Humans; Myocardium; Nitroglycerin; Piperazines; Ranolazine; Trimetazidine | 1993 |
Ranolazine: a novel metabolic modulator for the treatment of angina.
Topics: Acetanilides; Adenosine Triphosphate; Angina Pectoris; Clinical Trials as Topic; Enzyme Inhibitors; Fatty Acids; Glucose; Hemodynamics; Humans; Multicenter Studies as Topic; Oxidation-Reduction; Piperazines; Randomized Controlled Trials as Topic; Ranolazine | 1998 |
The use of ranolazine in cardiovascular disease.
Topics: Acetanilides; Angina Pectoris; Animals; Cardiovascular Diseases; Clinical Trials as Topic; Drug Approval; Energy Metabolism; Humans; Piperazines; Ranolazine | 2002 |
Clinical trials update: The Heart Protection Study, IONA, CARISA, ENRICHD, ACUTE, ALIVE, MADIT II and REMATCH. Impact Of Nicorandil on Angina. Combination Assessment of Ranolazine In Stable Angina. ENhancing Recovery In Coronary Heart Disease patients. As
Topics: Acetanilides; Angina Pectoris; Arrhythmias, Cardiac; Cardiology; Clinical Trials as Topic; Comorbidity; Coronary Disease; Defibrillators, Implantable; Depressive Disorder; Electric Countershock; Female; Heart Failure; Humans; Male; Nicorandil; Piperazines; Ranolazine; Sensitivity and Specificity | 2002 |
Partial fatty acid oxidation inhibitors for stable angina.
Topics: Acetanilides; Adenosine Triphosphate; Angina Pectoris; Chronic Disease; Energy Metabolism; Fatty Acids; Humans; Myocardium; Oxidation-Reduction; Oxygen Consumption; Piperazines; Ranolazine; Trimetazidine | 2002 |
32 trial(s) available for ranolazine and Angor Pectoris
| Article | Year |
|---|---|
Ranolazine After Incomplete Percutaneous Coronary Revascularization in Patients With Versus Without Diabetes Mellitus: RIVER-PCI Trial.
Topics: Aged; Angina Pectoris; Cardiovascular Agents; Diabetes Complications; Female; Glycated Hemoglobin; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Ranolazine | 2017 |
Late sodium channel blockade improves angina and myocardial perfusion in patients with severe coronary microvascular dysfunction: Women's Ischemia Syndrome Evaluation-Coronary Vascular Dysfunction ancillary study.
Topics: Adult; Aged; Angina Pectoris; Coronary Angiography; Coronary Artery Disease; Coronary Circulation; Cross-Over Studies; Double-Blind Method; Female; Humans; Microcirculation; Middle Aged; Myocardial Ischemia; Myocardial Perfusion Imaging; Ranolazine; Severity of Illness Index; Sodium Channel Blockers | 2019 |
Relationship Between Optimism and Outcomes in Patients With Chronic Angina Pectoris.
Topics: Aged; Angina Pectoris; Chronic Disease; Double-Blind Method; Female; Follow-Up Studies; Health Status; Humans; Male; Middle Aged; Morbidity; Myocardial Revascularization; Prognosis; Quality of Life; Ranolazine; Sodium Channel Blockers; United States | 2019 |
Ranolazine, ACE Inhibitors, and Angiotensin Receptor Blockers.
Topics: Acute Coronary Syndrome; Angina Pectoris; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Drug Interactions; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Myocardial Infarction; Ranolazine; Risk Assessment; Survival Rate; Treatment Outcome; United States; United States Food and Drug Administration | 2019 |
Effects of ivabradine and ranolazine in patients with microvascular angina pectoris.
Topics: Acetanilides; Analysis of Variance; Angina Pectoris; Benzazepines; Chi-Square Distribution; Coronary Angiography; Enzyme Inhibitors; Exercise Test; Female; Humans; Ivabradine; Male; Middle Aged; Piperazines; Placebos; Quality of Life; Ranolazine; Surveys and Questionnaires; Treatment Outcome | 2013 |
Cost-utility of ranolazine for the symptomatic treatment of patients with chronic angina pectoris in Spain.
Topics: Acetanilides; Angina Pectoris; Chronic Disease; Cost-Benefit Analysis; Enzyme Inhibitors; Female; Humans; Male; Markov Chains; Middle Aged; Piperazines; Placebos; Ranolazine; Spain | 2014 |
Use of ranolazine in patients with incomplete revascularization after percutaneous coronary intervention: design and rationale of the Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (RIVER-PCI) trial.
Topics: Acetanilides; Angina Pectoris; Double-Blind Method; Enzyme Inhibitors; Female; Hospitalization; Humans; Male; Percutaneous Coronary Intervention; Piperazines; Quality of Life; Ranolazine; Retreatment; Treatment Outcome | 2013 |
Comparison of the Seattle Angina Questionnaire With Daily Angina Diary in the TERISA Clinical Trial.
Topics: Acetanilides; Angina Pectoris; Coronary Artery Disease; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Enzyme Inhibitors; Follow-Up Studies; Humans; Incidence; Medical Records; Piperazines; Prospective Studies; Ranolazine; Surveys and Questionnaires; Treatment Outcome; United States | 2014 |
Effects of Ranolazine in Patients With Chronic Angina in Patients With and Without Percutaneous Coronary Intervention for Acute Coronary Syndrome: Observations From the MERLIN-TIMI 36 Trial.
Topics: Acute Coronary Syndrome; Aged; Angina Pectoris; Double-Blind Method; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Ranolazine; Recurrence; Sodium Channel Blockers; Treatment Outcome | 2015 |
Ranolazine in patients with incomplete revascularisation after percutaneous coronary intervention (RIVER-PCI): a multicentre, randomised, double-blind, placebo-controlled trial.
Topics: Aged; Angina Pectoris; Coronary Artery Disease; Coronary Stenosis; Double-Blind Method; Female; Hospitalization; Humans; Ischemic Attack, Transient; Male; Myocardial Infarction; Myocardial Ischemia; Myocardial Revascularization; Percutaneous Coronary Intervention; Ranolazine; Sodium Channel Blockers; Stroke | 2016 |
Effects of Ranolazine on Angina and Quality of Life After Percutaneous Coronary Intervention With Incomplete Revascularization: Results From the Ranolazine for Incomplete Vessel Revascularization (RIVER-PCI) Trial.
Topics: Aged; Aged, 80 and over; Angina Pectoris; Cardiovascular Agents; Double-Blind Method; Female; Humans; Male; Middle Aged; Myocardial Revascularization; Percutaneous Coronary Intervention; Quality of Life; Radiography; Ranolazine; Treatment Outcome | 2016 |
A randomized, placebo-controlled trial of late Na current inhibition (ranolazine) in coronary microvascular dysfunction (CMD): impact on angina and myocardial perfusion reserve.
Topics: Administration, Oral; Angina Pectoris; Coronary Disease; Cross-Over Studies; Double-Blind Method; Drug Administration Schedule; Female; Hemodynamics; Humans; Magnetic Resonance Angiography; Male; Medication Adherence; Microvessels; Middle Aged; Myocardial Ischemia; Quality of Life; Ranolazine; Sodium Channel Blockers; Treatment Outcome | 2016 |
Pharmacokinetic drug-drug interaction study of ranolazine and metformin in subjects with type 2 diabetes mellitus.
Topics: Adult; Aged; Angina Pectoris; Animals; Area Under Curve; Cardiovascular Agents; CHO Cells; Chronic Disease; Comorbidity; Cricetulus; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Interactions; Female; Humans; Hypoglycemic Agents; Male; Metabolic Clearance Rate; Metformin; Middle Aged; Organic Cation Transporter 2; Polypharmacy; Ranolazine; United States | 2015 |
Efficacy of ranolazine in patients with chronic angina observations from the randomized, double-blind, placebo-controlled MERLIN-TIMI (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Segment Elevation Acute Coronary Syndromes) 36 Trial.
Topics: Acetanilides; Acute Coronary Syndrome; Aged; Angina Pectoris; Chronic Disease; Cohort Studies; Confidence Intervals; Double-Blind Method; Enzyme Inhibitors; Exercise Test; Exercise Tolerance; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Ischemia; Piperazines; Proportional Hazards Models; Ranolazine | 2009 |
A study of the effects of ranolazine using automated quantitative analysis of serial myocardial perfusion images.
Topics: Acetanilides; Aged; Angina Pectoris; Automation, Laboratory; Cardiovascular Agents; Coronary Artery Disease; Coronary Circulation; Exercise Test; Exercise Tolerance; Female; Humans; Male; Middle Aged; Myocardial Ischemia; Myocardial Perfusion Imaging; Pilot Projects; Piperazines; Ranolazine; Severity of Illness Index; Tomography, Emission-Computed, Single-Photon; Treatment Outcome | 2009 |
Economic impact of angina after an acute coronary syndrome: insights from the MERLIN-TIMI 36 trial.
Topics: Acetanilides; Acute Coronary Syndrome; Aged; Ambulatory Care; Angina Pectoris; Costs and Cost Analysis; Enzyme Inhibitors; Female; Follow-Up Studies; Health Care Costs; Health Status; Hospitalization; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Piperazines; Quality of Life; Ranolazine; Surveys and Questionnaires | 2009 |
Improvement in left ventricular systolic and diastolic performance during ranolazine treatment in patients with stable angina.
Topics: Acetanilides; Administration, Oral; Aged; Aged, 80 and over; Angina Pectoris; Black or African American; Echocardiography, Doppler; Enzyme Inhibitors; Female; Follow-Up Studies; Humans; Male; Middle Aged; Piperazines; Ranolazine; Ventricular Dysfunction, Left | 2011 |
A pilot randomized study of ranolazine for reduction of myocardial damage during elective percutaneous coronary intervention.
Topics: Acetanilides; Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Biomarkers; Coronary Angiography; Creatine Kinase, MB Form; Double-Blind Method; Female; Humans; Male; Middle Aged; Myocardium; Pilot Projects; Piperazines; Ranolazine; Troponin I | 2012 |
Tolerability and pharmacokinetics of ranolazine following single and multiple sustained-release doses in Chinese healthy adult volunteers: a randomized, open-label, Latin square design, phase I study.
Topics: Acetanilides; Adult; Angina Pectoris; Area Under Curve; Asian People; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Piperazines; Ranolazine; Young Adult | 2013 |
Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial.
Topics: Acetanilides; Adrenergic beta-Antagonists; Aged; Amlodipine; Angina Pectoris; Atenolol; Calcium Channel Blockers; Cardiovascular Agents; Chronic Disease; Diltiazem; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; Exercise Test; Female; Hemodynamics; Humans; Male; Middle Aged; Myocardial Ischemia; Nitroglycerin; Physical Exertion; Piperazines; Ranolazine; Survival Analysis | 2004 |
Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina.
Topics: Acetanilides; Adult; Aged; Aged, 80 and over; Angina Pectoris; Dose-Response Relationship, Drug; Double-Blind Method; Enzyme Inhibitors; Exercise Test; Female; Humans; Male; Middle Aged; Piperazines; Ranolazine; Survival Analysis; Treatment Outcome | 2004 |
Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris.
Topics: Acetanilides; Adrenergic beta-Antagonists; Adult; Aged; Analysis of Variance; Angina Pectoris; Atenolol; Blood Pressure; Chronic Disease; Cross-Over Studies; Double-Blind Method; Enzyme Inhibitors; Exercise Test; Female; Heart Rate; Humans; Linear Models; Male; Middle Aged; Myocardial Ischemia; Piperazines; Ranolazine; Treatment Outcome | 2005 |
Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes.
Topics: Acetanilides; Aged; Angina Pectoris; Chronic Disease; Diabetic Angiopathies; Double-Blind Method; Enzyme Inhibitors; Exercise Tolerance; Female; Glycated Hemoglobin; Humans; Male; Nitroglycerin; Piperazines; Ranolazine; Treatment Outcome; Vasodilator Agents | 2006 |
Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial.
Topics: Acetanilides; Aged; Amlodipine; Angina Pectoris; Chronic Disease; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Incidence; Male; Middle Aged; Nitroglycerin; Piperazines; Ranolazine; Treatment Outcome; Vasodilator Agents | 2006 |
Gender comparison of efficacy and safety of ranolazine for chronic angina pectoris in four randomized clinical trials.
Topics: Acetanilides; Aged; Angina Pectoris; Enzyme Inhibitors; Female; Gender Identity; Humans; Male; Piperazines; Randomized Controlled Trials as Topic; Ranolazine; Severity of Illness Index; Surveys and Questionnaires | 2007 |
Long-term safety of a novel antianginal agent in patients with severe chronic stable angina: the Ranolazine Open Label Experience (ROLE).
Topics: Acetanilides; Administration, Oral; Adult; Aged; Angina Pectoris; Chronic Disease; Coronary Angiography; Dose-Response Relationship, Drug; Drug Administration Schedule; Electrocardiography; Enzyme Inhibitors; Exercise Test; Female; Follow-Up Studies; Humans; Long-Term Care; Male; Middle Aged; Piperazines; Probability; Proportional Hazards Models; Ranolazine; Risk Assessment; Severity of Illness Index; Single-Blind Method; Treatment Outcome | 2007 |
Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial.
Topics: Acetanilides; Aged; Angina Pectoris; Cardiovascular Agents; Double-Blind Method; Enzyme Inhibitors; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Piperazines; Proportional Hazards Models; Ranolazine; Recurrence | 2007 |
Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less Ischem
Topics: Acetanilides; Acute Disease; Aged; Angina Pectoris; Arrhythmias, Cardiac; Coronary Disease; Diabetic Angiopathies; Electrocardiography; Electrophysiology; Female; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Piperazines; Placebos; Ranolazine; Tachycardia; Thrombolytic Therapy | 2007 |
Effects of ranolazine on left ventricular regional diastolic function in patients with ischemic heart disease.
Topics: Acetanilides; Angina Pectoris; Blood Pressure; Female; Heart Rate; Humans; Infusions, Intravenous; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Piperazines; Ranolazine; Ventricular Function, Left | 1994 |
Double-blind efficacy and safety study of a novel anti-ischemic agent, ranolazine, versus placebo in patients with chronic stable angina pectoris. Ranolazine Study Group.
Topics: Acetanilides; Adult; Aged; Aged, 80 and over; Analysis of Variance; Angina Pectoris; Double-Blind Method; Drug Administration Schedule; Electrocardiography, Ambulatory; Exercise Test; Exercise Tolerance; Female; Humans; Male; Middle Aged; Piperazines; Ranolazine; Reproducibility of Results; Single-Blind Method | 1994 |
A controlled trial with a novel anti-ischemic agent, ranolazine, in chronic stable angina pectoris that is responsive to conventional antianginal agents. Ranolazine Study Group.
Topics: Acetanilides; Angina Pectoris; Cross-Over Studies; Double-Blind Method; Drug Administration Schedule; Enzyme Inhibitors; Exercise Test; Exercise Tolerance; Female; Humans; Male; Middle Aged; Piperazines; Ranolazine; Single-Blind Method | 1999 |
Effects of a new metabolic modulator, ranolazine, on exercise tolerance in angina pectoris patients treated with beta-blocker or diltiazem.
Topics: Acetanilides; Adrenergic beta-Antagonists; Adult; Aged; Analysis of Variance; Angina Pectoris; Blood Pressure; Diltiazem; Double-Blind Method; Drug Therapy, Combination; Exercise Test; Female; Heart Rate; Humans; Male; Middle Aged; Physical Exertion; Piperazines; Ranolazine | 1992 |
90 other study(ies) available for ranolazine and Angor Pectoris
| Article | Year |
|---|---|
Concomitant Use of Ranolazine and Trimetazidine in Patients with Refractory Angina: An Initial Experience.
Topics: Angina Pectoris; Angina, Stable; Cardiovascular Agents; Humans; Ranolazine; Treatment Outcome; Trimetazidine; Vasodilator Agents | 2022 |
Safety and efficacy of ranolazine in hypertrophic cardiomyopathy: Real-world experience in a National Referral Center.
Topics: Acetanilides; Angina Pectoris; Canada; Cardiomyopathy, Hypertrophic; Humans; Prospective Studies; Ranolazine; Treatment Outcome | 2023 |
Effect of ranolazine on symptom and quality of life in patients with angina in the absence of obstructive coronary artery disease: A case control study.
Topics: Angina Pectoris; Case-Control Studies; Coronary Artery Disease; Humans; Quality of Life; Ranolazine; Retrospective Studies; Treatment Outcome | 2020 |
Long-Term (3 Years) Outcomes of Ranolazine Therapy for Refractory Angina Pectoris (from the Ranolazine Refractory Registry).
Topics: Aged; Angina Pectoris; Cardiovascular Agents; Constipation; Deprescriptions; Diabetes Mellitus; Disease Progression; Dizziness; Drug Costs; Dyslipidemias; Edema; Female; Humans; Hypertension; Male; Medication Adherence; Middle Aged; Mortality; Myocardial Infarction; Myocardial Revascularization; Nausea; Ranolazine; Registries; Smoking; Treatment Failure; Treatment Outcome | 2020 |
Angina relates to coronary flow in women with ischemia and no obstructive coronary artery disease.
Topics: Angina Pectoris; Coronary Artery Disease; Coronary Circulation; Coronary Vessels; Female; Humans; Ischemia; Microcirculation; Myocardial Ischemia; Ranolazine | 2021 |
Ranolazine treatment in the heterogeneous symptomatic stable coronary artery disease population.
Topics: Aged; Angina Pectoris; Coronary Angiography; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Quality of Life; Ranolazine; Self Report; Sodium Channel Blockers; Treatment Outcome | 2018 |
Low Diastolic Blood Pressure Is Associated With Angina in Patients With Chronic Coronary Artery Disease.
Topics: Age Factors; Aged; Angina Pectoris; Blood Pressure; Body Mass Index; Cardiovascular Agents; Coronary Artery Disease; Cross-Sectional Studies; Diastole; Diuretics; Female; Humans; Logistic Models; Male; Nitrates; Ranolazine; Renal Insufficiency, Chronic; Sex Factors; United States | 2018 |
Treating Angina in Women: Improving Options and Outcomes.
Topics: Angina Pectoris; Female; Humans; Myocardial Ischemia; Ranolazine | 2019 |
Physical Activity After Percutaneous Coronary Intervention for Chronic Total Occlusion and Its Association With Health Status.
Topics: Aged; Angina Pectoris; Cardiovascular Agents; Chronic Disease; Coronary Occlusion; Exercise; Exercise Tolerance; Female; Follow-Up Studies; Health Status; Humans; Male; Middle Aged; Nitrates; Percutaneous Coronary Intervention; Ranolazine; Treatment Outcome | 2019 |
Role of Ranolazine in Reducing Angina, Subsequent Revascularization, and Healthcare Expenditures in Stable Ischemic Heart Disease.
Topics: Angina Pectoris; Health Expenditures; Humans; Myocardial Ischemia; Myocardial Revascularization; Ranolazine; Sodium Channel Blockers | 2019 |
De-escalation of antianginal medications after successful chronic total occlusion percutaneous coronary intervention: Frequency and relationship with health status.
Topics: Aged; Angina Pectoris; Calcium Channel Blockers; Cardiovascular Agents; Chi-Square Distribution; Chronic Disease; Coronary Occlusion; Dyspnea; Female; Health Status; Health Surveys; Humans; Logistic Models; Male; Myocardial Ischemia; Nitro Compounds; Percutaneous Coronary Intervention; Prospective Studies; Quality of Life; Ranolazine; Registries; Time Factors | 2019 |
Effects of the antianginal drug, ranolazine, on the brain sodium channel Na(V)1.2 and its modulation by extracellular protons.
Topics: Acetanilides; Angina Pectoris; Animals; Anti-Arrhythmia Agents; Anticonvulsants; Cardiotonic Agents; CHO Cells; Cricetulus; Extracellular Fluid; Hydrogen-Ion Concentration; Kinetics; NAV1.2 Voltage-Gated Sodium Channel; Nerve Tissue Proteins; Osmolar Concentration; Patch-Clamp Techniques; Piperazines; Protons; Ranolazine; Rats; Recombinant Proteins; Single-Cell Analysis; Voltage-Gated Sodium Channel Blockers | 2013 |
Impact of ranolazine on clinical outcomes and healthcare resource utilization in patients with refractory angina pectoris.
Topics: Acetanilides; Aged; Angina Pectoris; Female; Follow-Up Studies; Health Resources; Humans; Male; Middle Aged; Piperazines; Ranolazine; Retrospective Studies; Sodium Channel Blockers; Treatment Outcome | 2013 |
[Symptomatic coronary heart disease therapy: ranolazine reduces frequency of angina in diabetic patients].
Topics: Acetanilides; Angina Pectoris; Diabetes Complications; Humans; Piperazines; Placebo Effect; Randomized Controlled Trials as Topic; Ranolazine; Sodium Channel Blockers | 2013 |
[Angina pectoris. Ranolazine is effective in myocardial ischemia therapy].
Topics: Acetanilides; Angina Pectoris; Controlled Clinical Trials as Topic; Enzyme Inhibitors; Humans; Microvascular Angina; Piperazines; Ranolazine | 2013 |
[The TERISA study].
Topics: Acetanilides; Angina Pectoris; Diabetes Complications; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Humans; Piperazines; Randomized Controlled Trials as Topic; Ranolazine | 2013 |
Ranolazine refractory angina registry: 1-year results.
Topics: Acetanilides; Aged; Angina Pectoris; Data Interpretation, Statistical; Enzyme Inhibitors; Female; Humans; Male; Middle Aged; Patient Acuity; Patient Dropouts; Piperazines; Product Surveillance, Postmarketing; Ranolazine; Registries; Treatment Outcome; United States | 2014 |
Myopathy during treatment with the antianginal drug ranolazine.
Topics: Acetanilides; Angina Pectoris; Anticholesteremic Agents; Biopsy; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Humans; Middle Aged; Muscular Diseases; Piperazines; Ranolazine; Simvastatin; Treatment Outcome | 2014 |
Coronary artery disease: a dam in the river for ranolazine.
Topics: Angina Pectoris; Female; Humans; Male; Percutaneous Coronary Intervention; Ranolazine; Sodium Channel Blockers | 2016 |
Ranolazine for the symptomatic treatment of patients with chronic angina pectoris in Greece: a cost-utility study.
Topics: Angina Pectoris; Cardiovascular Agents; Chronic Disease; Cost-Benefit Analysis; Decision Trees; Dose-Response Relationship, Drug; Greece; Humans; Middle Aged; Quality of Life; Quality-Adjusted Life Years; Ranolazine; Standard of Care | 2015 |
Ranolazine following percutaneous coronary intervention: For whom? For what?
Topics: Angina Pectoris; Humans; Percutaneous Coronary Intervention; Ranolazine | 2016 |
[Drug therapy rarely fully utilized].
Topics: Angina Pectoris; Humans; Myocardial Ischemia; Quality of Life; Ranolazine | 2016 |
Long-Term Preservation of Left Ventricular Systolic Function in Patients With Refractory Angina Pectoris and Inducible Myocardial Ischemia on Optimal Medical Therapy.
Topics: Aged; Angina Pectoris; Benzazepines; Cardiovascular Agents; Echocardiography; Exercise Test; Female; Follow-Up Studies; Humans; Ivabradine; Male; Myocardial Ischemia; Ranolazine; Retrospective Studies; Sodium Channel Blockers; Stroke Volume; Systole; Time Factors; Tomography, Emission-Computed, Single-Photon; Trimetazidine; Vasodilator Agents; Ventricular Function, Left | 2016 |
Ranolazine for Treatment of Angina or Dyspnea in Hypertrophic Cardiomyopathy Patients (RHYME).
Topics: Aged; Angina Pectoris; Cardiomyopathy, Hypertrophic; Cardiovascular Agents; Dyspnea; Female; Humans; Male; Middle Aged; Pilot Projects; Ranolazine | 2016 |
Ranolazine for Refractory Angina in a Heart Transplant Recipient With Cardiac Allograft Vasculopathy.
Topics: Adult; Allografts; Angina Pectoris; Cardiovascular Agents; Drug Therapy, Combination; Heart Transplantation; Humans; Male; Ranolazine; Vascular Diseases | 2017 |
Expanding the understanding of the treatment of chronic angina: a 21st century approach--part 1.
Topics: Acetanilides; Angina Pectoris; Angioplasty, Balloon, Coronary; Chronic Disease; Coronary Artery Bypass; Enzyme Inhibitors; Humans; Incidence; Life Style; Patient Education as Topic; Piperazines; Ranolazine; Treatment Outcome; United States | 2008 |
The evolving role of medical therapy for chronic stable angina.
Topics: Acetanilides; Angina Pectoris; Angioplasty, Balloon, Coronary; Cardiovascular Agents; Chronic Disease; Combined Modality Therapy; Coronary Artery Bypass; Disease-Free Survival; Enzyme Inhibitors; Humans; Piperazines; Platelet Aggregation Inhibitors; Ranolazine; Risk Factors; Risk Reduction Behavior | 2008 |
Expanding the understanding of the treatment of chronic angina: a 21st century approach-part II.
Topics: Acetanilides; Angina Pectoris; Angioplasty, Balloon, Coronary; Chronic Disease; Enzyme Inhibitors; Humans; Myocardial Infarction; Myocardial Ischemia; Piperazines; Randomized Controlled Trials as Topic; Ranolazine | 2008 |
Determination of ranolazine in human plasma by liquid chromatographic-tandem mass spectrometric assay.
Topics: Acetanilides; Angina Pectoris; Biological Availability; Chromatography, Liquid; Enzyme Inhibitors; Humans; Piperazines; Ranolazine; Sensitivity and Specificity; Tandem Mass Spectrometry; Therapeutic Equivalency | 2008 |
Direct toxic effects of aqueous extract of cigarette smoke on cardiac myocytes at clinically relevant concentrations.
Topics: 1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt; Acetanilides; Angina Pectoris; Animals; Calcium; Cells, Cultured; Dose-Response Relationship, Drug; Enzyme Inhibitors; Free Radical Scavengers; Glucose; Heart Ventricles; Mice; Mitochondria, Heart; Mitochondrial Membrane Transport Proteins; Mitochondrial Permeability Transition Pore; Myocardial Contraction; Myocardial Infarction; Myocardial Ischemia; Myocytes, Cardiac; Nicotine; Piperazines; Rabbits; Ranolazine; Reactive Oxygen Species; Smoke; Smoking; Time Factors | 2009 |
Effects of ranolazine, a novel anti-anginal drug, on ion currents and membrane potential in pituitary tumor GH(3) cells and NG108-15 neuronal cells.
Topics: Acetanilides; Action Potentials; Angina Pectoris; Animals; Calcium Channels, L-Type; Cell Line; Cell Line, Tumor; Humans; Ion Channel Gating; Ion Transport; Membrane Potentials; Neurons; Patch-Clamp Techniques; Piperazines; Pituitary Neoplasms; Potassium Channels, Inwardly Rectifying; Ranolazine; Rats; Sodium Channels | 2009 |
FDA okays new drug for tough-to-treat chest pain.
Topics: Acetanilides; Angina Pectoris; Chest Pain; Drug Approval; Enzyme Inhibitors; Humans; Piperazines; Ranolazine; United States; United States Food and Drug Administration | 2006 |
Ranolazine: new drug. Stable angina: not worth the risk.
Topics: Acetanilides; Angina Pectoris; Arrhythmias, Cardiac; Cost-Benefit Analysis; Double-Blind Method; Drug Approval; Drug Interactions; Drug Therapy, Combination; Enzyme Inhibitors; Europe; Humans; Piperazines; Randomized Controlled Trials as Topic; Ranolazine | 2009 |
Ranolazine as a cardioplegia additive improves recovery of diastolic function in isolated rat hearts.
Topics: Acetanilides; Angina Pectoris; Animals; Diastole; Female; Heart Arrest, Induced; Myocardial Contraction; Myocardial Ischemia; Piperazines; Ranolazine; Rats; Rats, Sprague-Dawley; Sodium; Tetrodotoxin | 2009 |
Ranolazine, an antianginal agent, markedly reduces ventricular arrhythmias induced by ischemia and ischemia-reperfusion.
Topics: Acetanilides; Angina Pectoris; Animals; Anti-Arrhythmia Agents; Blood Pressure; Disease Models, Animal; Dose-Response Relationship, Drug; Electrocardiography; Female; Heart Rate; Infusions, Intravenous; Injections, Intravenous; Male; Myocardial Ischemia; Myocardial Reperfusion Injury; Piperazines; Ranolazine; Rats; Rats, Sprague-Dawley; Tachycardia, Ventricular; Time Factors; Ventricular Fibrillation | 2009 |
Ranolazine and the myocardial demand-supply balance.
Topics: Acetanilides; Angina Pectoris; Cardiovascular Agents; Coronary Artery Disease; Coronary Circulation; Exercise Test; Humans; Myocardial Ischemia; Myocardial Perfusion Imaging; Oxygen Consumption; Piperazines; Ranolazine; Severity of Illness Index; Tomography, Emission-Computed, Single-Photon; Treatment Outcome | 2009 |
[Ranolazine--new treatment of chronic stable angina pectoris].
Topics: Acetanilides; Angina Pectoris; Delayed-Action Preparations; Enzyme Inhibitors; Humans; Piperazines; Ranolazine; Treatment Outcome | 2009 |
Effects of ranolazine on wild-type and mutant hNav1.7 channels and on DRG neuron excitability.
Topics: Acetanilides; Angina Pectoris; Cell Line; Ganglia, Spinal; Humans; Mutation; NAV1.7 Voltage-Gated Sodium Channel; Piperazines; Ranolazine; Sodium Channel Blockers; Sodium Channels | 2010 |
The antianginal agent ranolazine is a potent antiarrhythmic agent that reduces ventricular arrhythmias: through a mechanism favoring inhibition of late sodium channel.
Topics: Acetanilides; Angina Pectoris; Animals; Anti-Arrhythmia Agents; Female; Piperazines; Ranolazine; Rats; Rats, Sprague-Dawley; Sodium Channel Blockers; Tachycardia, Ventricular | 2011 |
Ask the doctor. A year ago, I had an orchiectomy for prostate cancer; my PSA is now 0.74. Not long afterward, I had two cardiac stents implanted. I still have some angina and shortness of breath. I started Ranexa a couple of weeks ago, which helps my angi
Topics: Acetanilides; Angina Pectoris; Cardiovascular Agents; Health Knowledge, Attitudes, Practice; Humans; Male; Orchiectomy; Piperazines; Prostate-Specific Antigen; Prostatic Neoplasms; Ranolazine; Testosterone | 2010 |
Rhabdomyolysis in a patient receiving ranolazine and simvastatin.
Topics: Acetanilides; Angina Pectoris; Creatine Kinase; Drug Interactions; Enzyme Inhibitors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Piperazines; Ranolazine; Rhabdomyolysis; Simvastatin | 2010 |
Class I/B antiarrhythmic property of ranolazine, a novel antianginal agent, in dog and human cardiac preparations.
Topics: Acetanilides; Angina Pectoris; Animals; Anti-Arrhythmia Agents; Atrial Function; Dogs; Electrophysiological Phenomena; Female; Heart; Heart Atria; Humans; In Vitro Techniques; Kinetics; Male; Membrane Potentials; Papillary Muscles; Piperazines; Purkinje Fibers; Ranolazine | 2011 |
Effects of ranolazine on cardiovascular system.
Topics: Acetanilides; Angina Pectoris; Animals; Cardiovascular Diseases; Drug Design; Enzyme Inhibitors; Humans; Patents as Topic; Piperazines; Quality of Life; Ranolazine; United States | 2011 |
Metabolic antianginal agent ranolazine offers good symptom relief in a patient with inoperable severe aortic stenosis.
Topics: Acetanilides; Aged, 80 and over; Angina Pectoris; Aortic Valve Stenosis; Cardiovascular Agents; Female; Humans; Mitral Valve Stenosis; Piperazines; Ranolazine; Severity of Illness Index; Treatment Outcome | 2012 |
Effects of ranolazine on cloned cardiac kv4.3 potassium channels.
Topics: Acetanilides; Angina Pectoris; Animals; CHO Cells; Clone Cells; Cricetinae; Dose-Response Relationship, Drug; Kinetics; Myocardium; Patch-Clamp Techniques; Piperazines; Ranolazine; Shal Potassium Channels; Software; Transfection | 2011 |
Ranolazine injection into coronary or femoral arteries exerts marked, transient regional vasodilation without systemic hypotension in an intact porcine model.
Topics: Acetanilides; Adrenergic alpha-1 Receptor Agonists; Angina Pectoris; Animals; Blood Pressure; Coronary Vessels; Endothelium, Vascular; Femoral Artery; Humans; Models, Animal; Nitroglycerin; Piperazines; Prazosin; Ranolazine; Receptors, Adrenergic, alpha-1; Regional Blood Flow; Swine; Vascular Resistance; Vasodilation | 2011 |
The editor's roundtable: role of percutaneous coronary intervention and drug-eluting stents in patients with stable coronary heart disease.
Topics: Acetanilides; Acute Coronary Syndrome; Angina Pectoris; Angioplasty, Balloon, Coronary; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antithrombins; C-Reactive Protein; Cholesterol, LDL; Clinical Trials as Topic; Coronary Angiography; Coronary Artery Bypass; Coronary Circulation; Coronary Disease; Coronary Thrombosis; Cost-Benefit Analysis; Diabetes Mellitus; Drug-Eluting Stents; Enzyme Inhibitors; Heart; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Medical History Taking; Medication Adherence; Multidetector Computed Tomography; Myocardial Ischemia; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Radionuclide Imaging; Ranolazine; Risk Factors; Troponin | 2011 |
The use of ranolazine to facilitate electrical cardioversion in cardioversion-resistant patients: a case series.
Topics: Acetanilides; Aged; Angina Pectoris; Atrial Fibrillation; Electric Countershock; Enzyme Inhibitors; Female; Humans; Male; Middle Aged; Piperazines; Ranolazine; Retrospective Studies; Treatment Outcome | 2012 |
Costs and clinical outcomes associated with use of ranolazine for treatment of angina.
Topics: Acetanilides; Angina Pectoris; Cost-Benefit Analysis; Drug Costs; Female; Humans; Insurance Claim Review; Male; Middle Aged; Piperazines; Ranolazine; Treatment Outcome | 2012 |
[Update coronary artery disease: important progresses in acute and chronic therapy].
Topics: Acetanilides; Angina Pectoris; Angioplasty, Balloon, Coronary; Benzazepines; Coronary Artery Disease; Early Medical Intervention; Humans; Ivabradine; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Ranolazine; Survival Rate; Thrombolytic Therapy | 2012 |
Ranolazine-induced severe bladder hypotonia.
Topics: Acetanilides; Aged, 80 and over; Angina Pectoris; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Enzyme Inhibitors; Heart Failure; Humans; Male; Muscle Hypotonia; Piperazines; Ranolazine; Urinary Bladder Diseases; Urinary Retention | 2012 |
[Chronic ischemic heart diseases. Effectively alleviating ischemia symptoms].
Topics: Acetanilides; Angina Pectoris; Clinical Trials, Phase III as Topic; Coronary Circulation; Drug Therapy, Combination; Enzyme Inhibitors; Humans; Myocardial Ischemia; Piperazines; Practice Guidelines as Topic; Ranolazine | 2012 |
[Relative improvement of the quality of life (interview by Philip Gräzel)].
Topics: Acetanilides; Angina Pectoris; Drug Therapy, Combination; Enzyme Inhibitors; Humans; Myocardial Ischemia; Piperazines; Quality of Life; Ranolazine | 2012 |
Neurologic adverse effects of ranolazine in an elderly patient with renal impairment.
Topics: Acetanilides; Aged, 80 and over; Angina Pectoris; Dose-Response Relationship, Drug; Female; Humans; Kidney Diseases; Nervous System Diseases; Piperazines; Ranolazine | 2013 |
Partial fatty acid oxidation (pFOX) inhibition: a new therapy for chronic stable angina.
Topics: Acetanilides; Angina Pectoris; Energy Metabolism; Enzyme Inhibitors; Fatty Acids; Humans; Myocardial Contraction; Oxidation-Reduction; Piperazines; Ranolazine | 2003 |
A shift in myocardial substrate, improved endothelial function, and diminished sympathetic activity may contribute to the anti-anginal impact of very-low-fat diets.
Topics: Acetanilides; Angina Pectoris; Carnitine; Chemotherapy, Adjuvant; Diet, Fat-Restricted; Diet, Vegetarian; Endothelium, Vascular; Enzyme Inhibitors; Fatty Acids; Heart; Humans; Piperazines; Ranolazine; Sympathetic Nervous System | 2004 |
Report from the 100th Cardiovascular and Renal Drugs Advisory Committee meeting: US Food and Drug Administration: December 8-9, 2003 Gaithersburg, MD.
Topics: Acetanilides; Angina Pectoris; Aspirin; Clinical Trials as Topic; Delayed-Action Preparations; Drug Labeling; Humans; Maryland; Myocardial Infarction; Piperazines; Ranolazine | 2004 |
Ranolazine and other antianginal therapies in the era of the drug-eluting stent.
Topics: Acetanilides; Adrenergic beta-Antagonists; Angina Pectoris; Calcium Channel Blockers; Cardiovascular Agents; Drug Therapy, Combination; Humans; Myocardial Revascularization; Piperazines; Ranolazine; Risk | 2004 |
FDA evaluating new angina drug.
Topics: Acetanilides; Angina Pectoris; Chronic Disease; Drug Approval; Enzyme Inhibitors; Humans; Piperazines; Ranolazine; United States; United States Food and Drug Administration | 2004 |
Companies facing ethical issue as drugs are tested overseas.
Topics: Acetanilides; Angina Pectoris; Clinical Trials as Topic; Drug Approval; Drug Industry; Drugs, Investigational; Enzyme Inhibitors; Ethics, Business; Ethics, Research; Europe, Eastern; Humans; Internationality; Marketing; Piperazines; Quality of Life; Ranolazine; Research Subjects; Russia; United States | 2004 |
Ranolazine as add-on therapy for patients with severe chronic angina.
Topics: Acetanilides; Angina Pectoris; Antihypertensive Agents; Cardiovascular Agents; Chronic Disease; Drug Interactions; Drug Therapy, Combination; Enzyme Inhibitors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Piperazines; Ranolazine | 2004 |
Ranolazine as add-on therapy for patients with severe chronic angina.
Topics: Acetanilides; Angina Pectoris; Cardiovascular Agents; Chronic Disease; Drug Therapy, Combination; Enzyme Inhibitors; Humans; Piperazines; Ranolazine | 2004 |
Effects of very low-fat diets on anginal symptoms.
Topics: Acetanilides; Angina Pectoris; Carnitine; Chemotherapy, Adjuvant; Diabetes Complications; Diabetes Mellitus; Diet, Fat-Restricted; Diet, Vegetarian; Endothelium, Vascular; Enzyme Inhibitors; Fatty Acids; Heart; Humans; Piperazines; Randomized Controlled Trials as Topic; Ranolazine; Treatment Outcome | 2004 |
Efficacy and safety of a metabolic modulator drug in chronic stable angina: review of evidence from clinical trials.
Topics: Acetanilides; Administration, Oral; Aged; Angina Pectoris; Aryl Hydrocarbon Hydroxylases; Chronic Disease; Clinical Trials as Topic; Cross-Over Studies; Delayed-Action Preparations; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Interactions; Electrocardiography; Energy Metabolism; Exercise Test; Female; Humans; Long QT Syndrome; Male; Piperazines; Randomized Controlled Trials as Topic; Ranolazine; Single-Blind Method; Survival Analysis; Time Factors; Treatment Outcome | 2004 |
[Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina. Results of CARISA].
Topics: Acetanilides; Adrenergic beta-Antagonists; Amlodipine; Angina Pectoris; Atenolol; Cardiovascular Agents; Chronic Disease; Diltiazem; Double-Blind Method; Exercise Test; Humans; Multicenter Studies as Topic; Piperazines; Placebos; Randomized Controlled Trials as Topic; Ranolazine; Time Factors; Vasodilator Agents | 2004 |
Myocardial metabolism: a new target for the treatment of heart disease?
Topics: Acetanilides; Angina Pectoris; Coronary Artery Disease; Enzyme Inhibitors; Exercise Test; Humans; Myocardium; Piperazines; Randomized Controlled Trials as Topic; Ranolazine | 2004 |
Ranolazine CV Therapeutics.
Topics: Acetanilides; Angina Pectoris; Animals; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Enzyme Inhibitors; Humans; Molecular Structure; Piperazines; Ranolazine | 2005 |
Chronic stable angina.
Topics: Acetanilides; Angina Pectoris; Chronic Disease; Drug Interactions; Enzyme Inhibitors; Humans; Hypotension; Nitrates; Phosphodiesterase Inhibitors; Piperazines; Ranolazine; Time Factors | 2005 |
Ranolazine is associated with cardiovascular and metabolic improvement: a win-win for patients with diabetes.
Topics: Acetanilides; Angina Pectoris; Cardiotonic Agents; Diabetic Angiopathies; Exercise Tolerance; Humans; Piperazines; Ranolazine | 2006 |
Anti-angina drug shifts heart muscle's fuel use. Compelling the heart to burn more blood sugar and less fat appears to boost cardiac efficiency.
Topics: Acetanilides; Angina Pectoris; Blood Glucose; Enzyme Inhibitors; Fatty Acids; Humans; Myocardium; Piperazines; Ranolazine | 2002 |
New drugs for prevention, relief. How you might benefit if 3 medications win FDA approval.
Topics: Acetanilides; Angina Pectoris; Benzazepines; Heart Failure; Humans; Obesity; Piperazines; Piperidines; Pyrazoles; Ranolazine; Rimonabant; Tolvaptan | 2005 |
Ranolazine and late cardiac sodium current--a therapeutic target for angina, arrhythmia and more?
Topics: Acetanilides; Angina Pectoris; Animals; Arrhythmias, Cardiac; Long QT Syndrome; Mutation; Myocytes, Cardiac; NAV1.5 Voltage-Gated Sodium Channel; Piperazines; Ranolazine; Sodium; Sodium Channel Blockers; Sodium Channels | 2006 |
Ranolazine (ranexa) for chronic angina.
Topics: Acetanilides; Angina Pectoris; Chronic Disease; Clinical Trials as Topic; Drug Interactions; Enzyme Inhibitors; Humans; Piperazines; Ranolazine | 2006 |
Ranolazine, a novel anti-anginal agent, does not alter isosorbide dinitrate- or sildenafil-induced changes in blood pressure in conscious dogs.
Topics: Acetanilides; Angina Pectoris; Animals; Blood Pressure; Dogs; Enzyme Inhibitors; Heart Rate; Hypotension; Injections, Intravenous; Isosorbide Dinitrate; Male; Piperazines; Purines; Ranolazine; Sildenafil Citrate; Stimulation, Chemical; Sulfones; Vasodilator Agents | 2006 |
Mechanism of action of ranolazine.
Topics: Acetanilides; Angina Pectoris; Calcium; Coronary Circulation; Humans; Piperazines; Ranolazine; Sodium Channels; Treatment Outcome | 2006 |
Ranolazine.
Topics: Acetanilides; Angina Pectoris; Calcium; Humans; Piperazines; Randomized Controlled Trials as Topic; Ranolazine; Sodium | 2006 |
New angina medication approved.
Topics: Acetanilides; Angina Pectoris; Chronic Disease; Delayed-Action Preparations; Humans; Piperazines; Ranolazine | 2006 |
Drug approvals.
Topics: Acetanilides; Alprostadil; Angina Pectoris; Benzazepines; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Drug Approval; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Enzyme Inhibitors; Fatty Acids; Herpes Zoster Vaccine; Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; Humans; Ibandronic Acid; Insulin; Lubiprostone; Naltrexone; Narcotic Antagonists; Nurse's Role; Papillomavirus Vaccines; Patient Education as Topic; Piperazines; Quinoxalines; Ranolazine; Triazoles; United States; United States Food and Drug Administration; Varenicline | 2007 |
Does ranolazine have a place in the treatment of acute coronary syndromes?
Topics: Acetanilides; Angina Pectoris; Cardiovascular Agents; Enzyme Inhibitors; Humans; Myocardial Infarction; Piperazines; Ranolazine | 2007 |
New options help angina patients live more active lives. Treating the underlying disease may help you live longer, too.
Topics: Acetanilides; Angina Pectoris; Cardiotonic Agents; Coronary Disease; Counterpulsation; Female; Humans; Male; Piperazines; Ranolazine | 2007 |
Ranolazine--a nicely timed new medical therapy for stable angina.
Topics: Acetanilides; Angina Pectoris; Enzyme Inhibitors; Humans; Piperazines; Ranolazine | 2007 |
Metabolic efficiency with ranolazine for less ischemia in non-ST elevation acute coronary syndromes (MERLIN TIMI-36) study.
Topics: Acetanilides; Acute Coronary Syndrome; Acute Disease; Angina Pectoris; Cardiovascular Agents; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Enzyme Inhibitors; Female; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Quality of Life; Randomized Controlled Trials as Topic; Ranolazine; Recurrence; Sex Factors; Thrombolytic Therapy | 2008 |
[Therapeutic application of myocardial cytoprotection].
Topics: Acetanilides; Adrenergic beta-Antagonists; Angina Pectoris; Calcium Channel Blockers; Carnitine; Humans; Myocardial Ischemia; Niacinamide; Nicorandil; Piperazines; Ranolazine; Trimetazidine; Vasodilator Agents | 1994 |
Cardioprotective effects of ranolazine (RS-43285) in the isolated perfused rabbit heart.
Topics: Acetanilides; Adenosine Triphosphate; Angina Pectoris; Animals; Calcium; Creatine Kinase; Dose-Response Relationship, Drug; Heart; Microscopy, Electron; Myocardial Ischemia; Myocardial Reperfusion Injury; Myocardium; Perfusion; Piperazines; Potassium; Rabbits; Ranolazine; Ventricular Pressure | 1994 |
Protective effects of ranolazine in guinea-pig hearts during low-flow ischaemia and their association with increases in active pyruvate dehydrogenase.
Topics: Acetanilides; Adenosine Triphosphate; Angina Pectoris; Animals; Creatine Kinase; Female; Glycogen; Guinea Pigs; Heart; In Vitro Techniques; L-Lactate Dehydrogenase; Lactates; Lactic Acid; Myocardial Ischemia; Myocardium; Perfusion; Phosphocreatine; Piperazines; Pyruvate Dehydrogenase Complex; Ranolazine | 1993 |
Effects of ranolazine on ischemic threshold, coronary sinus blood flow, and myocardial metabolism in coronary artery disease.
Topics: Acetanilides; Aged; Alanine; Angina Pectoris; Blood Pressure; Citric Acid; Coronary Circulation; Coronary Disease; Enzyme Inhibitors; Fatty Acids; Glucose; Glutamic Acid; Heart Rate; Humans; Lactic Acid; Male; Middle Aged; Myocardium; Piperazines; Ranolazine | 1997 |
Antianginal effects of ranolazine in various experimental models of angina.
Topics: Acetanilides; Administration, Oral; Adrenergic beta-Antagonists; Anesthesia; Angina Pectoris; Animals; Atenolol; Dogs; Duodenum; Electrocardiography; Epinephrine; Female; Intubation, Gastrointestinal; Male; Myocardial Ischemia; Piperazines; Ranolazine; Rats; Rats, Wistar; Vasoconstrictor Agents; Vasopressins | 1999 |
New angina drugs on the horizon?
Topics: Acetanilides; Allopurinol; Angina Pectoris; Clinical Trials as Topic; Enzyme Inhibitors; Humans; Piperazines; Ranolazine | 2002 |
Ranolazine (RS-43285): a preliminary study of a new anti-anginal agent with selective effect on ischaemic myocardium.
Topics: Acetanilides; Angina Pectoris; Animals; Blood Pressure; Coronary Disease; Electrocardiography; Exercise Test; Heart Rate; Nitroglycerin; Piperazines; Ranolazine; Single-Blind Method | 1990 |
The effects of the novel anti-anginal compound RS 43285 on myocardial conduction in the anaesthetized dog.
Topics: Acetanilides; Anesthesia; Angina Pectoris; Animals; Atrioventricular Node; Dogs; Electrocardiography; Heart Conduction System; Male; Nicardipine; Nifedipine; Piperazines; Ranolazine; Verapamil | 1988 |